Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL

Clinical and Experimental Immunology

Volumn 124, Issue 1, 2001, Pages 163-167

  Swets, B P ^a   Brouwer, D A J ^a   Cohen Tervaert, J W ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Autoantibodies; Oxidized LDL; Vasculitis

Indexed keywords

AUTOANTIBODY; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE;

ADULT; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; REMISSION; SYSTEMIC VASCULITIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODY SPECIFICITY; ARTERIOSCLEROSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DISEASE SUSCEPTIBILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0035009320     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01488.x     Document Type: Article

References (30)

1. 1 Cupps TR, Fauci AS. The vasculitic syndromes. Adv Intern Med 1982; 28:315-44.
2. 2 Conn DL. Update on systemic necrotizing vasculitis. Mayo Clin Proc 1989; 64:535-43.
3. 3 Juvonen T, Juvonen J, Savo Painen MJ. Is vasculitis a significant component of atherosclerosis? Curr Opin Rheumatol 1999; 11:3-10.
4. 4 Jian-Hua Qiao, Castellani LW, Fishbein MC, Lusis AJ. Immune-complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler Thromb 1993; 13:932-43.
5. 5 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-9.
6. 6 Lehtimäki T, Lehtinen S, Solakivi T, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19:23-8.
7. 7 Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1988; 84:2995-8.
8. 8 Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low-density lipoprotein. Proc Natl Acad Sci USA 1985; 82:5949-53.
9. 9 Muller Kobold AC, van Der Geld YM, Limburg PC, Cohen Tervaert JW, Kallenberg CGM. Pathophysiology of ANCA-associated glomerulonephritis. Nephrol Dial Transplant 1999; 14:1366-85.
10. 10 Steinbrecher UP, Fischer M, Witzum JL et al. Immunogenicity of homologous low-density lipoprotein after methylation, ethylation, acetylation or carbamylation: Generation of antibodies specific for derivatyzed lysine. J Lipid Res 1984; 25:1109-16.
11. 11 Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modifications in vivo. Proc Natl Acad Sci USA 1989; 86:1382-6.
12. 12 Armstrong VW, Wieland E, Diedrich F, Renner A, Rath W, Kreuzer H, Kuhn W, Oellerich M. Serum antibodies to oxidized low-density lipoprotein in pre-eclampsia and coronary heart disease. Lancet 1994; 343:1580.
13. 13 Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertension 1995; 13:129-38.
14. 14 Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15:441-5.
15. 15 Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883-8.
16. 16 Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 38:188-92.
17. 17 Redgrave TG, Roberts DCK, West CE. Separation of plasma lipoproteins by density gradient ultracentrifugation. Anal Biochem 1975; 65:42-9.
18. 18 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-75.
19. 19 Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10:325-35.
20. 20 Wu R, Svenungsson E, Gunnarsson I, Haegerstrand-Gillis C, Andersson B, Lundberg I, Elinder LS, Frostegård J. Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and β2-glycoprotein I (β2-GPI) in systemic lupus erythematosus. Clin Exp Immunol 1999; 115:561-6.
21. 21 Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341:923-5.
22. 22 Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115-9.
23. 23 Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 1992; 141:335-42.
24. 24 Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antobodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992; 41:375-83.
25. 25 Johnson RJ, Guggenheim SJ, Klebanoff SJ, Ochi RF, Wass A, Baker P, Schulze M, Couser WG. Morphologic correlates of glomerular oxidant injury induced by the myeloperoxidase-hydrogen peroxide-halide system of the neutrophil. Lab Invest 1988; 5:294-301.
26. 26 Deventer SJH, Kastelein JJP, Ten Cate JW. Atherosclerose mede veroorzaakt door lokale vaatontsteking. Ned Tijdschr Geneeskd 1994; 138:443-8.
27. 27 Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.
28. 28 Mulder AHL, Stegeman CA, Kallenberg CGM. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995; 101:227-32.
29. 29 Witztum JL, Palinski W. Are immunological mechanisms relevant for the development of atheroslcerosis. Clin Immunol 1999; 90:153-6.
30. 30 Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15:1569-7631.